- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin secured tentative U.S. FDA approval for its Sugammadex Injection, a generic equivalent to Merck's Bridion®. This positive business development opens a new market opportunity for the company in surgical neuromuscular blockade reversal.